鼻内免疫重组痘病毒表达三聚体SARS-CoV-2刺突受体结合域诱导中和抗体
研究构建携带SARS-CoV-2刺突蛋白三聚体受体结合域(RBD)的重组痘病毒(VV-tRBD),对小鼠和兔进行鼻内免疫。BALB/c小鼠鼻内免疫后产生强效体液和细胞免疫应答,血清中针对SARS-CoV-2假病毒的中和IgG和IgA水平高,并产生RBD特异性IFN-γ分泌淋巴细胞;兔血清也显示中和效果。鼻洗液和支气管肺泡灌洗液中可检测到RBD特异性分泌型IgA(sIgA)并显示中和活性。作者认为重组VV表达三聚体RBD可诱导强效全身免疫应答和黏膜中和抗体,值得进一步探索作为黏膜疫苗。
要点
- 鼻内免疫VV-tRBD在小鼠中诱导强效体液和细胞免疫应答
- 小鼠血清中中和IgG和IgA水平高,兔血清也显示中和效果
- 鼻洗液和支气管肺泡灌洗液中可检测到RBD特异性sIgA并具中和活性
核心结论
- 重组VV表达三聚体RBD可诱导强效全身免疫应答和黏膜中和抗体,值得进一步探索作为黏膜疫苗。
研究设计与样本
- 构建携带SARS-CoV-2刺突蛋白三聚体RBD的重组痘病毒(VV-tRBD),对BALB/c小鼠和兔进行鼻内免疫并评估针对RBD的免疫应答。
主要发现
- BALB/c小鼠鼻内免疫VV-tRBD后产生强效体液和细胞免疫应答,血清中针对SARS-CoV-2假病毒的中和IgG和IgA水平高,并产生RBD特异性IFN-γ分泌淋巴细胞。
- 免疫兔的血清也显示中和效果。
- 鼻洗液和支气管肺泡灌洗液中可检测到RBD特异性sIgA并显示中和活性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者在结论中提出值得进一步探索作为黏膜疫苗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Respiratory transmission of SARS-CoV-2 is considered to be the major dissemination route for COVID-19, therefore, mucosal immune responses have great importance in preventing SARS-CoV-2 from infection. In this study, we constructed a recombinant Vaccinia virus (VV) harboring trimeric receptor-binding domain (RBD) of SARS-CoV-2 spike protein (VV-tRBD), and evaluated the immune responses towards RBD following intranasal immunization against mice and rabbits. In BALB/c mice, intranasal immunization with VV-tRBD elicited robust humoral and cellular immune responses, with high-level of both neutralizing IgG and IgA in sera against SARS-CoV-2 psudoviruses, and a number of RBD-specific IFN-γ-secreting lymphocytes. Sera from immunized rabbits also exhibited neutralization effects. Notably, RBD-specific secretory IgA (sIgA) in both nasal washes and bronchoalveolar lavage fluids (BALs) were detectable and showed substantial neutralization activities. Collectively, a recombinant VV expressing trimeric RBD confers robust systemic immune response and mucosal neutralizing antibodies, thus warranting further exploration as a mucosal vaccine.
引用
- Cao X, Zai J, Zhao Q, et al. Intranasal immunization with recombinant Vaccinia virus encoding trimeric SARS-CoV-2 spike receptor-binding domain induces neutralizing antibody. Vaccine. 2022. PMID: 36055873. doi:10.1016/j.vaccine.2022.08.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。